Blog Big Molecule Watch April 25, 2019

Alvotech and Fuji Pharma Partner to Commercialize Alvotech’s Ustekinumab Biosimilar

Earlier this month, Alvotech announced that it entered into an agreement with Fuji Pharma, giving Fuji Pharma the exclusive right to commercialize its biosimilar of Stelara® (ustekinumab) in Japan.  The press release states that, in exchange for developing and providing Fuji Pharma with a commercial supply of its ustekinumab biosimilar, Alvotech will receive an upfront payment of $4.6 million with rights to receive milestone payments of up to $20 million.

The post Alvotech and Fuji Pharma Partner to Commercialize Alvotech’s Ustekinumab Biosimilar appeared first on Big Molecule Watch.